Key Highlights
- Revenue increased USD 6.0 million, or 13.5%, to USD 50.2 million from USD 44.2 million.
- Services Revenue increased 17.8% to USD 28.6 million, and Products revenue increased 8.4% to USD 21.7 million.
- Commercial Cell and Gene Therapy revenue within Services increased 29.0% to USD 9.6 million, from USD 7.4 million.
- The company supported 788 Clinical Trials globally at September 30, 2026, of which 99 were in phase 3.
Cryoport, Inc. (NASDAQ:CYRX) reported third quarter 2026 revenue of USD 50.2 million, an increase of USD 6.0 million, or 13.5%, from USD 44.2 million. EPS was negative USD 0.25.
Life Sciences Services
Life Sciences Services revenue increased USD 4.3 million, or 17.8%, from USD 24.3 million to USD 28.6 million. The company attributed the increase to year-over-year growth in BioLogistics Solutions revenue of 15.9% and BioStorage and BioServices revenue of 25.1%, which it said demonstrates strong Demand for its services offerings.
Commercial Cell and Gene Therapy revenue included in Services increased USD 2.2 million, or 29.0%, from USD 7.4 million to USD 9.6 million, and included BioLogistics and BioStorage revenue of USD 9.0 million and USD 0.6 million, compared with USD 7.4 million and zero a year earlier.
Cryoport continued to gain clinical trial market share, supporting a total of 788 clinical trials globally at September 30, 2026, of which 99 were in phase 3. Revenue from the support of cell and gene therapy clinical trials included in Services revenue was USD 13.4 million, up 15.5% from USD 11.6 million.
Life Sciences Products and Margins
Life Sciences Products revenue increased USD 1.7 million, or 8.4%, from USD 20.0 million to USD 21.7 million. Commercial Cell and Gene Therapy revenue within Products was USD 0.4 million versus USD 0.9 million, and revenue from the support of cell and gene therapy clinical trials was USD 0.3 million in both periods.
Gross Margin was 47.5% of total revenue versus 48.2%. Cost of total revenue increased USD 3.5 million, or 15.2%, to USD 26.4 million from USD 22.9 million. Gross margin for Life Sciences Services was 50.4% versus 49.7%, and for Life Sciences Products it was 43.6% versus 46.4%.
Operating Expenses
SG&A expenses increased USD 1.2 million, or 4.4%, compared with the same period in 2025, primarily driven by increases of USD 0.7 million in cost reduction initiatives, USD 0.2 million in Marketing costs and USD 0.1 million in travel expenses. Engineering and development expenses increased USD 0.2 million, or 4.7%. Investment income decreased USD 0.4 million, and interest expense remained substantially unchanged.
Other income (expense), net decreased USD 4.9 million, primarily due to a USD 4.8 million increase in short-term investment net unrealized losses and a USD 0.1 million increase in foreign currency losses. The provision for income taxes remained substantially unchanged, resulting in effective tax rates of negative 1.8% and negative 2.5%, respectively, with the increase in the rate due primarily to a larger pretax loss.
Disclosed items include the split of growth between BioLogistics and BioStorage, the commercial therapy contribution, the clinical trial count by phase and the gross margin movements in each segment. Reported detail: Commercial Cell and Gene Therapy revenue within Services increased 29.0% to USD 9.6 million, from USD 7.4 million.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...